Long Term Effect of Oxaliplatin Treatment in Cancer Survivors

Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Nov 18, 2016

Keywords

ClinConnect Summary

Oxaliplatin remains the reference treatment of advanced colorectal cancer and more broadly of digestive cancers, incorporated in the FOLFOX protocol (folinic acid, 5-Fu, Oxaliplatin). But oxaliplatin chemotherapy is certainly the most neurotoxic, as on average 90% of patients develop acute neuropathic disorders (within hours or days of the infusion) and 30% to 50% of patients develop a chronic neuropathy with repeated cycles of chemotherapy. The neuropathic grade and duration of symptoms remain variable across studies. Although symptoms improve with time, long-term studies suggest a persist...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Living patient who received adjuvant chemotherapy (FOLFOX).
• • Patient in remission.
• • FOLFOX chemotherapy over for 0-5 years.
• • Oral Non-opposition to participation in the study
• Exclusion Criteria:
• • • Patient unable to understand or respond to questionnaires.
• • Age \<18 years.
• • Neurological diseases (eg Parkinson's disease, stroke, fibromyalgia ...).
• • Legal incapacity (person deprived of liberty or under guardianship).